Tag: blood cell

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical...

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity Novel Globin-Switching mechanism derived from...

European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome...

LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA¹

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that...

MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications

PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor,...

AS JUNE 19 WORLD SICKLE CELL AWARENESS DAY APPROACHES, COLLABORATIVE OF 47 COMMUNITY-BASED ORGANIZATIONS AND MEDICAL PROVIDERS PREPARE TO ‘SHINE THE LIGHT ON SICKLE...

COMMUNITY ACTION CAMPAIGN TO ILLUMINATE COMMUNITIES, RAISE AWARENESS, CALL FOR A UNIVERSAL CURE IN SUPPORT OF SICKLE CELL WARRIORS Historically African American Sororities And Fraternities...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsBlood cell

REE Automotive Receives Nasdaq Minimum Bid Price Notification

Dalai Lama’s 90th: A Global Celebration of Compassion, Peace, and Wisdom

Hope Regional Cancer Center Earns Prestigious ACR Accreditation for Excellence in Cancer Care